Regulus Therapeutics

RGLS56

Penny Stock

$1.54arrow_drop_up0.65%$0.01

Penny Stock

RGLS56

$1.54

arrow_drop_up0.65%$0.01

Penny Stock

Performance History

Key Stats
Open	$1.47
Prev. Close	$1.53
EPS	-1.02
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$100.21M
PE Ratio	-

	LOW	HIGH
Day Range	1.47	1.54
52 Week Range	1.08	3.79

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.02

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc is a biopharmaceutical company that is focused on the discovery and development of innovative medicines targeting microRNAs. The company's mission is to harness the power of these molecules to transform the treatment of serious diseases. MicroRNAs are small RNA molecules that play a critical role in regulating gene expression. By selectively targeting these molecules, Regulus is able to modulate the activity of specific genes and potentially therapeutic effect.

Regulus Therapeutics Inc operates with the belief that microRNAs represent a new class of drug targets with the potential to revolutionize medicine. The company's unique approach is based on the extensive research and expertise in the field of microRNA biology. Regulus has developed a proprietary platform that enables the identification, validation, and optimization of microRNA therapeutics. This platform allows the company to screen and select the most promising candidates for further development.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Headquarters: San Diego
Employees: 30
Exchange: NASDAQ

Keep an eye on Regulus Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Regulus Therapeutics 's (RGLS) price per share?

The current price per share for Regulus Therapeutics (RGLS) is $1.54. The stock has seen a price change of $0.01 recently, indicating a 0.65% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Regulus Therapeutics (RGLS)?

For Regulus Therapeutics (RGLS), the 52-week high is $3.79, which is 146.1% from the current price. The 52-week low is $1.08, the current price is 42.59% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Regulus Therapeutics (RGLS) a growth stock?

Regulus Therapeutics (RGLS) has shown an average price growth of -3.4% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Regulus Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Regulus Therapeutics (RGLS) stock price performance year to date (YTD)?

As of the latest data, Regulus Therapeutics (RGLS) has a year-to-date price change of 17.56%. Over the past month, the stock has experienced a price change of 2.67%. Over the last three months, the change has been -16.76%. Over the past six months, the figure is -24.69%. Looking at a longer horizon, the five-year price change stands at -79.74%.

help

Is Regulus Therapeutics (RGLS) a profitable company?

Regulus Therapeutics (RGLS) has a net income of -$30.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$31.11M. Furthermore, the EBITDA is -$44.26M.

help

What is the market capitalization of Regulus Therapeutics (RGLS)?

Regulus Therapeutics (RGLS) has a market capitalization of $100.22M. The average daily trading volume is 1.54, indicating the stock's liquidity and investor engagement.